Volume 17, Number 1—January 2011
Research
Completeness of Communicable Disease Reporting, North Carolina, USA, 1995–1997 and 2000–2006
Emily E. Sickbert-Bennett
, David J. Weber, Charles Poole, Pia D.M. MacDonald, and Jean-Marie Maillard
, David J. Weber, Charles Poole, Pia D.M. MacDonald, and Jean-Marie Maillard
Table
. Disease-specific reporting completeness proportions in North Carolina, USA, 2000–2006*
| Communicable disease | No. reported to NC DHHS | No. identified by ICD-9-CM codes | Unadjusted RCP, % (95% CI) | Semi-Bayesian adjusted RCP, % (95% UI) |
|---|---|---|---|---|
| Anthrax | 0 | 14 | 0.01 (0.00–100.00) | 0.00 (0.00–100.00) |
| Arboviral encephalitis | 0 | 18 | 0.00 (0.00–100.00) | 8.67 (0.80–52.77) |
| Botulism | 0 | 4 | 0.02 (0.00–100.00) | 0.08 (0.00–100.00) |
| Brucellosis | 0 | 33 | 0.00 (0.00–100.00) | 23.02 (1.36–86.62) |
| Campylobacteriosis | 39 | 97 | 40.21 (30.94–50.22) | 39.96 (30.82–49.85) |
| Cholera | 0 | 6 | 0.01 (0.00–100.00) | 18.58 (2.24–69.41) |
| CJD/vCJD | 0 | 32 | 0.00 (0.00–100.00) | 0.87 (0.03–22.97) |
| Cryptosporidiosis | 10 | 84 | 11.90 (6.53–20.73) | 12.59 (7.07–21.42) |
| Cyclosporiasis | 0 | 3 | 0.03 (0.00–100.00) | 18.59 (2.25–69.42) |
| Dengue | 4 | 25 | 16.00 (6.14–35.69) | 14.48 (5.92–31.31) |
| Diphtheria | 0 | 5 | 0.02 (0.00–100.00) | 8.28 (0.82–49.70) |
| Escherichia coli infection | 1 | 3 | 33.33 (4.34–84.65) | 24.67 (5.82–63.45) |
| Foodborne staphylococcal infection | 0 | 14 | 0.01 (0.00–100.00) | 74.74 (16.74–97.76) |
| Granulocytic ehrlichiosis | 0 | 67 | 0.00 (0.00–100.00) | 8.66 (0.80–52.74) |
| Hantavirus infection | 0 | 3 | 0.03 (0.00–100.00) | 10.10 (0.62–67.06) |
| Hemolytic uremic syndrome | 5 | 429 | 1.17 (0.49–2.77) | 2.20 (0.99–4.84) |
| Hemophilus Influenzae | 14 | 1,086 | 1.29 (0.76–2.16) | 1.45 (0.87–2.42) |
| Hepatitis A | 27 | 866 | 3.12 (2.15–4.51) | 3.34 (2.31–4.81) |
| Legionellosis | 24 | 98 | 24.49 (16.99–33.95) | 24.04 (16.72–33.27) |
| Leptospirosis | 0 | 33 | 0.00 (0.00–100.00) | 23.02 (1.36–86.62) |
| Listeriosis | 10 | 64 | 15.63 (8.62–26.67) | 16.14 (9.12–26.95) |
| Lyme disease | 8 | 790 | 1.01 (0.51–2.01) | 1.18 (0.60–2.30) |
| Malaria | 17 | 155 | 10.97 (6.93–16.94) | 10.71 (6.80–16.47) |
| Measles | 0 | 14 | 0.01 (0.00–100.00) | 15.98 (1.41–71.63) |
| Meningococcal disease | 38 | 179 | 21.23 (15.85–27.83) | 21.19 (15.85–27.73) |
| Monocytic ehrlichiosis | 1 | 4 | 25.00 (3.35–76.22) | 14.84 (3.12–48.52) |
| Mumps | 1 | 96 | 1.04 (0.15–7.02) | 1.07 (0.20–5.49) |
| Plague | 0 | 28 | 0.00 (0.00–100.00) | 0.00 (0.00–100.00) |
| Pneumococcal meningitis | 20 | 191 | 10.47 (6.86–15.67) | 10.61 (6.99–15.80) |
| Polio, paralytic | 0 | 32 | 0.00 (0.00–100.00) | 18.56 (2.24–69.38) |
| Psittacosis | 0 | 21 | 0.00 (0.00–100.00) | 17.45 (1.57–73.69) |
| Q fever | 3 | 14 | 21.43 (7.07–49.43) | 25.68 (9.14–54.28) |
| Rabies, human | 0 | 12 | 0.01 (0.00–100.00) | 59.69 (8.00–96.19) |
| Rocky Mountain spotted fever | 40 | 986 | 4.06 (2.99–5.48) | 4.19 (3.10–5.66) |
| Rubella | 0 | 39 | 0.00 (0.00–100.00) | 15.97 (1.41–71.61) |
| Rubella congenital syndrome | 0 | 10 | 0.01 (0.00–100.00) | 1.08 (0.07–15.32) |
| Salmonellosis | 263 | 594 | 44.28 (40.33–48.30) | 44.82 (40.87–48.83) |
| SARS (coronavirus infection) | 0 | 1 | 0.08 (0.00–100.00) | 5.71 (0.28–56.27) |
| Shigellosis | 38 | 213 | 17.84 (13.26–23.57) | 18.17 (13.56–23.93) |
| Smallpox | 0 | 9 | 0.01 (0.00–100.00) | 0.00 (0.00–100.00) |
| Streptococcal infection, group A | 8 | 111 | 7.21 (3.65–13.75) | 7.40 (3.80–13.92) |
| Tetanus | 1 | 20 | 5.00 (0.70–28.22) | 5.25 (1.09–21.78) |
| Toxic shock syndrome | 4 | 142 | 2.82 (1.06–7.26) | 3.22 (1.28–7.83) |
| Trichinosis | 0 | 23 | 0.00 (0.00–100.00) | 20.21 (1.82–77.58) |
| Tuberculosis | 100 | 1,439 | 6.95 (5.74–8.38) | 7.10 (5.87–8.55) |
| Tularemia | 0 | 6 | 0.01 (0.00–100.00) | 0.04 (0.00–100.00) |
| Typhoid, acute | 3 | 12 | 25.00 (8.28–55.18) | 21.57 (7.49–48.30) |
| Typhus, epidemic (louse-borne) | 0 | 2 | 0.04 (0.00–100.00) | 2.93 (0.12–42.63) |
| Vaccinia | 0 | 13 | 0.01 (0.00–100.00) | 8.27 (0.82–49.68) |
| Vibrio spp. infection, other | 0 | 1 | 0.08 (0.00–100.00) | 81.58 (20.46–98.71) |
| Vibrio vulnificus infection | 0 | 2 | 0.04 (0.00–100.00) | 81.57 (20.45–98.71) |
| Whooping cough (pertussis) | 11 | 54 | 20.37 (11.65–33.16) | 20.31 (11.78–32.72) |
| Yellow fever | 0 | 3 | 0.03 (0.00–100.00) | 8.69 (0.80–52.81) |
*NC DHHS, North Carolina Department of Health and Human Services; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; RCP, reporting completeness proportions; CI, confidence interval; UI, uncertainty interval; CJD, Creutzfeldt-Jakob disease; vCJD, variant CJD; SARS, severe acute respiratory syndrome.
Page created: July 08, 2011
Page updated: July 08, 2011
Page reviewed: July 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.